Institute of Hematology & Blood Diseases Hospital, China: Precursor Cell Lymphoblastic Leukemia-Lymphoma trials

The registry lists 28 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor. 21 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 1 5Phase 2 14Phase 3 4No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic MalignanciesEnrolling by invitationNCT07784309Phase 1
• Plasma ctDNA Monitoring in Pediatric Acute LeukemiaNot yet recruitingNCT07751588
• Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic LeukemiaRecruitingNCT07495631Not applicable
• ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALLRecruitingNCT07454226Not applicable
• Newly-diagnosed Pediatric Ph-positive B-ALL ProtocolRecruitingNCT07152041Phase 3
• Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous LineageNot yet recruitingNCT06991920Not applicable
• Newly-diagnosed Low Risk Pediatric B-cell ALL ProtocolRecruitingNCT06882057Phase 2/3
• Newly-diagnosed Pediatric T-cell ALL ProtocolRecruitingNCT06855810Phase 2/3
• Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolRecruitingNCT06764238Phase 2/3
• Blinatumomab as Maintenance Therapy in Patients With High-risk B-lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell TransplantationNot yet recruitingNCT06658938Not applicable
• Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALLNot yet recruitingNCT06658925Phase 2
• Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.RecruitingNCT06608732Phase 2
• Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic LeukemiaRecruitingNCT06608342Phase 2
• Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALLRecruitingNCT06481241Not applicable
• Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALLRecruitingNCT06481228Not applicable
• the Efficacy and Safety of Total Myeloid Irradiation (TMI) in the Treatment of Adult Acute Lymphoblastic LeukemiaNot yet recruitingNCT06461091
• Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic LeukemiaRecruitingNCT06427330Phase 2
• Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALLRecruitingNCT06387121Phase 2
• A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma PatientsNot yet recruitingNCT06087419Phase 1/2
• Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic LeukemiaRecruitingNCT05660473Phase 2
• Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALLRecruitingNCT05495035Phase 1
• Daratumumab for T Cell ALL With MRD-positive After Standard ChemotherapyWithdrawnNCT06570915Phase 2
• Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALLCompletedNCT05594784Phase 2
• Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction ChemotherapyActive, not recruitingNCT05456698Phase 2
• A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic LeukemiaTerminatedNCT05292898Phase 1
• CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)TerminatedNCT04034446Early Phase 1
• CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic LeukemiaCompletedNCT02975687Phase 1
• Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaCompletedNCT02523976Phase 2